Suppr超能文献

难治性感染的治疗:临床医生面临的新挑战。

Treatment of refractory infection: A new challenge for clinicians.

作者信息

Xu XinBo, He Cong, Zhu Yin

机构信息

Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital of Nanchang University, Nanchang, China.

出版信息

Front Microbiol. 2022 Oct 18;13:998240. doi: 10.3389/fmicb.2022.998240. eCollection 2022.

Abstract

Patients who have failed two or more attempts to eradicate are commonly referred to as refractory. Although the incidence of refractory infection is only 10-20%, with the increasing rate of antibiotic resistance in various regions, the treatment of refractory infection has gradually become a difficult problem faced by clinicians. When choosing a rescue therapy, the physician must consider numerous factors. A longer treatment duration, higher doses of proton pump inhibitors (PPIs), or the use of potassium-competitive acid blocker (P-CAB) may increase the efficacy of triple therapy or bismuth quadruple therapy. Rescue treatment based on bismuth quadruple therapy usually achieves better results. At the same time, treatment based on drug susceptibility tests or genotypic resistance is recommended where available. Of course, appropriate empiric treatment can also be selected according to local drug resistance, a patient's previous medication history and compliance. It is the best choice if it can improve the success rate of the first treatment and reduce the occurrence of refractory infection. This review aims to summarize the articles related to refractory in recent years and to explore a better remedial treatment plan for clinicians.

摘要

根除治疗失败两次或以上的患者通常被称为难治性患者。尽管难治性感染的发生率仅为10%-20%,但随着各地区抗生素耐药率的上升,难治性感染的治疗逐渐成为临床医生面临的难题。选择挽救治疗时,医生必须考虑众多因素。延长治疗时间、增加质子泵抑制剂(PPI)剂量或使用钾离子竞争性酸阻滞剂(P-CAB)可能会提高三联疗法或铋剂四联疗法的疗效。基于铋剂四联疗法的挽救治疗通常能取得更好的效果。同时,在可行的情况下,建议根据药敏试验或基因型耐药情况进行治疗。当然,也可根据当地耐药情况、患者既往用药史和依从性选择合适的经验性治疗。如果能提高首次治疗的成功率并减少难治性感染的发生,那就是最佳选择。本综述旨在总结近年来与难治性相关的文章,并为临床医生探索更好的补救治疗方案。

相似文献

1
Treatment of refractory infection: A new challenge for clinicians.
Front Microbiol. 2022 Oct 18;13:998240. doi: 10.3389/fmicb.2022.998240. eCollection 2022.
2
Treatment of Refractory Infection-Tailored or Empirical Therapy.
Gut Liver. 2022 Jan 15;16(1):8-18. doi: 10.5009/gnl20330.
4
Second-line rescue treatment of infection: Where are we now?
World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548.
5
Rescue therapy for refractory infection: current status and future concepts.
Therap Adv Gastroenterol. 2023 May 6;16:17562848231170941. doi: 10.1177/17562848231170941. eCollection 2023.
6
Toward population specific and personalized treatment of Helicobacter pylori infection.
J Biomed Sci. 2018 Oct 2;25(1):70. doi: 10.1186/s12929-018-0471-z.
7
A new look at anti-Helicobacter pylori therapy.
World J Gastroenterol. 2011 Sep 21;17(35):3971-5. doi: 10.3748/wjg.v17.i35.3971.
9
Best Eradication Strategy in the Era of Antibiotic Resistance.
Antibiotics (Basel). 2020 Jul 23;9(8):436. doi: 10.3390/antibiotics9080436.
10
Practical Aspects in Choosing a Helicobacter pylori Therapy.
Gastroenterol Clin North Am. 2015 Sep;44(3):519-35. doi: 10.1016/j.gtc.2015.05.004. Epub 2015 Jun 19.

引用本文的文献

2
Multidisciplinary Approach Improves Eradication Rate and Safety in Refractory Helicobacter pylori Infection.
Clin Transl Gastroenterol. 2025 Feb 1;16(2):e00804. doi: 10.14309/ctg.0000000000000804.
3
Optimized sequential therapy 10- and 14-d concomitant therapy for eradicating : A randomized clinical trial.
World J Gastroenterol. 2024 Feb 14;30(6):556-564. doi: 10.3748/wjg.v30.i6.556.
4
Analysis of Helicobacter pylori resistance in patients with different gastric diseases.
Sci Rep. 2024 Feb 28;14(1):4912. doi: 10.1038/s41598-024-55589-2.

本文引用的文献

1
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
Mini Rev Med Chem. 2022;22(19):2430-2437. doi: 10.2174/1389557522666220325153832.
3
TCM-Based Therapy as a Rescue Therapy for Re-Eradication of Infection: A Systematic Review and Meta-Analysis.
Evid Based Complement Alternat Med. 2022 Feb 24;2022:5626235. doi: 10.1155/2022/5626235. eCollection 2022.
6
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2243-2257. doi: 10.1016/j.cgh.2021.12.025. Epub 2021 Dec 23.
7
Chinese Consensus Report on Family-Based Infection Control and Management (2021 Edition).
Gut. 2022 Feb;71(2):238-253. doi: 10.1136/gutjnl-2021-325630. Epub 2021 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验